drugset / Trial / NCT02179567
Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC
NaSingle-groupOpen-labelTreatment
Summary
The investigators propose to study the efficacy and safety of the combination of Docetaxel plus Bevacizumab in a Phase II trial of elderly subjects with non-small cell lung cancer
Timeline
- Start
- 2010-03
- Primary completion
- 2013-03
- Completion
- 2013-03
Outcome
Outcome not reported
Stopped (Enrollment): “Terminated due to poor accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Docetaxel | Small molecule | 60 mg/m2 | Intravenous |